Toxic Adenoma other imaging findings

	Toxic Adenoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Toxic Adenoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Template:T On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Toxic Adenoma other imaging findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Toxic Adenoma other imaging findings
CDC on Toxic Adenoma other imaging findings
Toxic Adenoma other imaging findings in the news
Blogs on Toxic Adenoma other imaging findings
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Toxic Adenoma other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

Radionuclide imaging and quantitative radioisotopic uptake studies are always required to establish the diagnosis of toxic adenoma or toxic nodular goiter
Radionuclide imaging can be performed with radioactive iodine-123 ( 123 I) or with technetium-99m ( 99m Tc).
Radionuclide imaging performed with 123 I or 99m Tc-technetium pertechnetate, are trapped by the sodium-iodide symporter in functioning thyroid tissue, although only radioiodine is subsequently organified.
In patients with hyperthyroidism caused by a toxic adenoma, there is a characteristic restriction of radionuclide uptake to the responsible hyper functioning nodule with suppression of radionuclide uptake in the remainder of the gland.
In a patient with a low serum TSH concentration, not only does the scan appearance support the diagnosis of toxic adenoma, but in almost all cases it also excludes malignancy in the nodule.
If some thyroid nodules are hypo functioning, it is necessary to rule out cancer by fine-needle aspiration cytology.

Differential for thyrotoxicosis	Fractional Uptake of Radioactive Iodine in 24 hrs (%)	Radioactive iodine Distrubution
Graves’ disease	40-95	Diffuse (Homogeneous within thyroid)
Toxic adenoma	20-60	Restricted to autonomous regions in thyroid
Subacute thyroiditis	<2	minimal uptake
Silent thyroiditis	<2	minimal uptake
Iodine-induced thyrotoxicosis	<2	minimal uptake
Factitious or iatrogenic thyrotoxicosis	<2	minimal uptake
Struma ovarii	<2	Uptake in ovary
Follicular carcinoma	<2	Uptake in cancer metastasis
Thyroid-stimulating hormone–induced thyrotoxicosis	30-80	Diffuse (Homogeneous within thyroid)